Immunometabolism modulator - Lmito Therapeutics
Latest Information Update: 06 Feb 2023
Price :
$50 *
At a glance
- Originator Lmito Therapeutics
- Class Antirheumatics
- Mechanism of Action Immunomodulators; Metabolism-modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 28 Dec 2022 Preclinical trials in Rheumatoid arthritis in South Korea (unspecified route) (Lmito Therapeutics pipeline, December 2022)